India, Nov. 16 -- Rein Therapeutics (RNTX), a clinical-stage biopharmaceutical company developing treatments for pulmonary and fibrotic diseases, reported preliminary blinded observations from its ongoing Phase 2 RENEW trial evaluating inhaled LTI-03 in patients with idiopathic pulmonary fibrosis (IPF), along with third-quarter 2026 financial results.

Company Profile

Rein Therapeutics is developing first-in-class therapies for pulmonary and fibrotic diseases. Its lead candidate, LTI-03, is an investigational inhaled peptide designed to protect lung cells and inhibit fibrosis in patients with IPF. Its second candidate, LTI-01, is being developed for loculated pleural effusions.

Third-Quarter 2026 Financial Results

Research and developmen...